TNFRSF10D Antibody Pair

Structure and Function

TNFRSF10D, also known as TRAIL-R4 or decoy receptor 2 (DCR2), is a type I transmembrane protein that binds TRAIL but lacks the death domain necessary for apoptosis induction. Instead, it inhibits TRAIL-mediated apoptosis by competing with death receptors (DR4/DR5) for ligand binding . The antibody pair consists of:

• Capture Antibody: Coated on a solid-phase substrate (e.g., ELISA plate) to bind TNFRSF10D in samples.

• Detection Antibody: Conjugated with enzymes (e.g., horseradish peroxidase) or fluorescent tags to enable signal detection .

Applications

The TNFRSF10D Antibody Pair is employed in:

Cancer Studies

• Elevated TNFRSF10D expression correlates with tumor progression and resistance to TRAIL-based therapies in non-small cell lung cancer (NSCLC) .

• Antibody pair-based assays revealed higher TNFRSF10D levels in NSCLC tumor tissues compared to non-tumor tissues (P=0.013), with significant associations in male and non-smoker subgroups .

Immune Disorders

• TNFRSF10D expression is implicated in rheumatoid arthritis, where TRAIL promotes synovial fibroblast proliferation via MAPK and PI3K/Akt pathways .

Clinical Trials

• The antibody pair supports biomarker analysis in trials testing TRAIL agonists (e.g., dulanermin) for cancer treatment .

Challenges and Limitations

• Optimization: Requires precise antibody dilution and assay conditions .

• Sample Type: Limited to soluble TNFRSF10D in ELISA; membrane-bound detection may require alternative methods .